Gene editing: beyond the hype
CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo
0 Comment
gene editing
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Stem cell transplant eradicates HIV in second patient
gene editing, HIV, infectious disease, stem cell therapy
0 Comment
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug
Allergan, blindness, CRISPR/Cas9, Editas, gene editing, Leber’s Congenital Amaurosis, ophthalmology
0 Comment
4th Annual Genome Editing USA Congress
cas9, CRISPR, gene editing, Genome Editing, Genome Engineering
0 Comment
2 days, 350+ end users, 80+ case studies
CRISPR trials yield encouraging data in blood disorders
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Novo Nordisk builds in haemophilia with Bluebird Bio gene editing deal
bluebird bio, gene editing, genetic, Haematology, haemophilia, Novo Nordisk
0 Comment